Prevalence of Non-Alcoholic Fatty Liver Disease and Its Predictors in North of Iran - PubMed (original) (raw)

. 2014 Sep;43(9):1275-83.

Affiliations

Prevalence of Non-Alcoholic Fatty Liver Disease and Its Predictors in North of Iran

Bahareh Amirkalali et al. Iran J Public Health. 2014 Sep.

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is one of the aspects of metabolic syndrome (MetS). Due to the increase of MetS in Iran, this study was conducted to determine the prevalence of NAFLD, its potential predictors and their sex distribution in north of Iran, Amol.

Methods: In 2008 this population based cross-sectional study included 5023 adult individuals who were randomly selected from Amol healthcare centers. Blood analysis and hepatic sonography was performed for each individual and Clinical histories were reviewed. MetS was defined according to the National Cholesterol Education Program Adult Treatment Panel III. Chi-square test, univariate and multivariate logistic regression were used to analyze data.

Results: The prevalence of NAFLD and metabolic syndrome was 43.8% and 29.6% respectively. Both NAFLD and metabolic syndrome were significantly more prevalent in women. There was a stronger association between these two factors in women which may indicate MetS has a much more potency to result in NAFLD in women. The strongest predictors of NAFLD in men were waist circumference>102 cm, serum ALT ≥40 (U/L) and the age group of 40-60 years. The strongest predictors of NAFLD in women were waist circumference>88 cm, the age groups of 40-60 and >60 years.

Conclusions: The observed prevalence is alarming because almost 7out of 10 subjects with MetS had NAFLD. As high waist circumference was an important predictor of NAFLD in both sexes, health care policies to reduce the incidence of obesity in the country will have an important impact on the occurrence of NAFLD.

Keywords: Metabolic syndrome; Non-Alcoholic fatty liver disease (NAFLD); Risk factors.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Alba L, Lindor K (2003). Non-alcoholic fatty liver disease. Aliment Pharmacol Ther, 17 (8): 977–86. - PubMed
    1. Angulo P (2007). GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther, 25 (8): 883–9. - PubMed
    1. Clark JM, Brancati FL, Diehl AM (2002). Nonalcoholic fatty liver disease. Gastroenterology, 122 (6): 1649–57. - PubMed
    1. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. (2005). Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 41 (6): 1313–21. - PubMed
    1. Lattuada G, Ragogna F, Perseghin G (2011). Why Does NAFLD Predict Type 2 Diabetes? Curr Diab Rep, 11 (3): 167–72. - PubMed

LinkOut - more resources